Company Description
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide.
The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments.
The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.
The Neuromodulation segment designs, develops, markets, and sells VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve; difficult-to-treat depression and drug-resistant epilepsy devices.
The Advanced Circulatory Support segment develops, produces, and sells temporary life support products.
It serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers.
The company sells its products through direct sales representatives and independent distributors. LivaNova PLC was incorporated in 2015 and is headquartered in London, the United Kingdom.
| Country | United Kingdom |
| Founded | 1987 |
| IPO Date | Feb 10, 1993 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 2,900 |
| CEO | Vladimir Makatsaria |
Contact Details
Address: 20 Eastbourne Terrace London, W2 6LG United Kingdom | |
| Phone | 44 20 3325 0660 |
| Website | livanova.com |
Stock Details
| Ticker Symbol | LIVN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001639691 |
| CUSIP Number | G5509L101 |
| ISIN Number | GB00BYMT0J19 |
| Employer ID | 98-1268150 |
| SIC Code | 3845 |
Key Executives
| Name | Position |
|---|---|
| Vladimir A. Makatsaria | Chief Executive Officer and Director |
| Michael D. Hutchinson | Senior Vice President, Chief Legal Officer and Company Secretary |
| Lindsey Little | Senior Director of Investor Relations |
| Deanna Wilke | Vice President of Corporate Communications |
| Matthew Joseph Dodds III | Senior Vice President of Corporate Development and IT |
| Paul R. Buckman | President of Advanced Circulatory Support and GM of Transcatheter Mitral Valve Replacement |
| Stephanie Bolton | President of Global Epilepsy |
| Ahmet Tezel Ph.D. | Chief Innovation Officer |
| Franco Poletti | President of Cardiopulmonary Business Unit |
| John Webb | Vice President of Sleep Apnea and Epilepsy |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 1, 2024 | 8-K | Current Report |
| Oct 31, 2024 | IRANNOTICE | Notice of disclosure filed pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 |
| Oct 31, 2024 | 10-Q | Quarterly Report |
| Oct 30, 2024 | 8-K | Current Report |
| Oct 8, 2024 | 8-K | Current Report |
| Sep 11, 2024 | 144 | Filing |
| Sep 10, 2024 | 8-K | Current Report |
| Aug 1, 2024 | IRANNOTICE | Notice of disclosure filed pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 |
| Aug 1, 2024 | 10-Q | Quarterly Report |
| Jul 31, 2024 | 8-K | Current Report |